Vasogen - Developing Therapies Targeting Inflammation

We are focused on the research and commercial development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease. Inflammation is a normal response of the immune system to cellular injury caused by infection, trauma, or other stimuli. During the inflammatory process, immune cells release a number of factors, including cytokines - potent chemical messengers that modulate inflammation and facilitate the healing process. While inflammation is normally self-limiting, it can persist and become chronic. Advances in medical research have established the fundamental role of chronic inflammation in the development and progression of a number of serious conditions, including heart failure, atherosclerosis, and certain neurodegenerative diseases.

Our Celacade™ System has received European regulatory approval under the CE Mark for the treatment of chronic heart failure and is being marketed in the E.U. Celacade is also in late-stage development for the treatment of chronic heart failure in the U.S. We are also developing VP025, an early-stage drug candidate for the treatment of certain neurodegenerative diseases.

---